… new evidence on the effectiveness of memantine, it remains less … cost-effectiveness are
quite different from the previous assessment. This is because both the changes in effectiveness …

… Methods: we conducted a health technology assessment (HTA) of the effectiveness and
cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of …

… true cost-effectiveness of memantine). In the current review, the cost-effectiveness of memantine
… using the industry model, the cost-effectiveness is reported at between 37,000 pounds …

… (donepezil, galantamine, rivastigmine, and memantine) from its list of reimbursable treatments
[45]. If our US cost-effectiveness … , this 2018 policy decision in effect denies treatment that …

… We studied whether donepezil, galantamine, rivastigmine, or memantine are cost-effective …
’s disease already on donepezil were randomized to (i) continue donepezil; (ii) discontinue …

… The cost-effectiveness of memantine for patients with … the acceptance of donepezil,
memantine and rivastigmine when … revealed the cost-effectiveness of AChEIs and memantine for …

… economic evaluations of donepezil, galantamine, rivastigmine, and memantine. Understanding
… that assessed the cost-effectiveness of combination therapy (memantine and one of the …

… (donepezil, rivastigmine, and galantamine) and memantine concluded that there were small
benefits in cognition in patients with mild to moderate vascular dementia over 24-28 weeks, …

… Cost-effectiveness of donepezil and memantine in moderateto severe Alzheimer's disease
(… effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine …

… AChE inhibitors (donepezil, galantamine and rivastigmine) … disease (AD) and memantine
recommended as an option for … cost-effectiveness consequences of continuing donepezil …